Last reviewed · How we verify
NCT05133037
AN/BN Risk Factors Study
trial testing GE MR Scanner in Eating Disorders in 50 participants. Participants enrolled and being followed up; not accepting new ones.
6 June 2025
Quick facts
| Lead sponsor | Stanford University |
|---|---|
| Status | Active, enrolled |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 23 November 2021 |
| Primary completion | 6 June 2025 |
| Estimated completion | 26 May 2029 |
| Sites | 1 location across United States |
Drugs / interventions tested
- GE MR Scanner
Conditions studied
- Eating Disorders — all drugs for Eating Disorders →
Sponsor
Stanford University
Who can join
Adults 12 to 16, female only, with Eating Disorders. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Across the United States, thousands of children and adolescents suffer from eating disorders. Among young women alone, an estimated 2 to 4 percent are dealing with anorexia nervosa. Anorexia nervosa also has the highest mortality rate of any psychiatric disorder and produces a six-fold increased risk for death. Unfortunately, study shows that current treatments are only successful with 25 percent of patients and no eating disorder prevention program has been found to reduce future onset of anorexia nervosa. The goal of this study is to conduct a highly innovative pilot study that will identify risk factors that predict future onset of anorexia nervosa and investigate how the risk processes for anorexia nervosa are different from the risk processes for bulimia nervosa. The proposed pilot study will: * Compare 30 healthy adolescent girls at high risk for anorexia nervosa to 30 healthy adolescent girls at high risk for bulimia nervosa, and 30 healthy adolescent girls at low risk for eating disorder in an effort to document risk processes that are present in early adolescence before anorexia nervosa typically emerges. * Test whether elevations in the hypothesized risk factors predict future onset of anorexia nervosa over a four-year follow-up.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT05133037
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Eating Disorders
Currently open trials in the same condition.
- NCT07237607 — Developing an Artificial Intelligence (AI) Chatbot for Adolescents and Young Adults With Eating Disorders · NA · recruiting
- NCT07295197 — Oral Indicators for ED Screening · recruiting
- NCT07082777 — Recovery in Telling Life Stories · NA · recruiting
- NCT07042672 — Behavioral Therapy and GLP-1 Analogue Effects on Binge Eating, Weight, and Coping in Obesity · recruiting
- NCT07017322 — Non-invasive Cranial Electrical Stimulation for Mealtime Anxiety in Adults With Eating Disorders · NA · recruiting
Other Stanford University trials
Trials by the same sponsor.
- NCT05945147 — Ketamine and Midazolam Infusions for CRPS: Feasibility Study · Phase 2 · withdrawn
- NCT04225949 — Patients Understanding of PROM Graphs · NA · withdrawn
- NCT06273098 — School-Based Bladder Health Intervention · NA · withdrawn
- NCT04652635 — Management of Nailbed Injuries · NA · withdrawn
- NCT05443503 — Stanford Spine Keeper - Managing Your Low Back Pain · NA · suspended
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT05133037 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Stanford University
- Last refreshed: 28 August 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT05133037.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing